ClinicalTrials.gg
CompletedNCT07945600Updated Nov 18, 2026

Prospective Cohort Study of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis Aggravating Extrahepatic Organ Damage

An observational study in NAFLD and NASH (Non-Alcoholic Steatohepatitis), sponsored by Beijing Tsinghua Chang Gung Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Beijing Tsinghua Chang Gung Hospital · Observational

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
36
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 53 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Enrollment
53rd of 54
36 · median 740
Started
2025
with 10 others
Observational
54 of 143
23 open now
Registered
143rd of 143
by date
Lead sponsor
3 of 143
Beijing Tsinghua Chang Gung Hospital

Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 53rd largest by enrollment of the 54 observational ones that give a count, is one of 11 that started in 2025, is one of 54 observational ones, and was the 143rd registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

The goal of this observational prospective cohort study is to explore the impacts and potential molecular mechanisms of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) on extrahepatic organ injury in adult patients scheduled for partial hepatectomy. The main questions it aims to answer are:

Do patients with NAFLD/NASH suffer more severe extrahepatic organ injury compared with patients without NAFLD/NASH? Are inflammatory mediators (IL-2, IL-6, IL-11) associated with the severity of NAFLD/NASH and extrahepatic organ damage?

Researchers will compare the NAFLD/NASH group (n=18) with the non-NAFLD/NASH group (n=18) to see if NAFLD/NASH aggravates extrahepatic organ injury and correlates with elevated levels of serum and urinary inflammatory mediators .

Participants will:

  • Provide 3 mL preoperative venous blood sample and 5 mL mid-stream urine sample for detection of inflammatory mediators.
  • Undergo partial hepatectomy; small pieces of resected liver tissue will be collected for HE staining and Oil-Red-O staining for histopathological evaluation and disease-staging.
  • Complete routine preoperative baseline assessments including demographic data, medical history, laboratory tests and instrumental examinations.
  • Receive clinical laboratory and instrumental examinations related to liver and extrahepatic organ function within 7 days after surgery for outcome evaluation.
03

Conditions studied

  • NAFLD
  • NASH (Non-Alcoholic Steatohepatitis)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Study subjects are adult patients with definite preoperative diagnoses scheduled for partial hepatectomy, who are enrolled from the Hepatobiliary-Pancreatic Center, Beijing Tsinghua Changgung Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Aged ≥ 18 years; (2) Definite preoperative diagnosis; (3) Scheduled for partial hepatectomy; (4) Voluntarily participate in this study and provide signed

Exclusion criteria

Exclusion Criteria:

  • (1) Patient refusal; (2) Viral hepatitis, including hepatitis, alcoholic liver disease or other toxic liver diseases; (3) History of acute or chronic infectious diseases within two weeks prior to blood testing; (4) Pregnancy; (5) Presence of comorbidities that may affect the evaluation of endpoint outcomes; (6) Conditions rendering the patient ineligible for enrollment as judged by the attending physician; (7) Participation in another concurrent study that may interfere with the outcome assessment of this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
36 participants (actual)
Target follow-up
7 Days
Patient registry
Yes

Groups and cohorts

  • Participants with NAFLD/NASH(n=18)

    Other: Not applicable- observational study

  • Participants without NAFLD/NASH(n=18)

    Other: Not applicable- observational study

Interventions

  • OtherNot applicable- observational study

    Not applicable- observational study

06

What researchers measure

Primary outcomes

  1. Differences in laboratory and instrumental examination results related to various extrahepatic organs related to various extrahepatic organs between the two groups

    Time frame: at baseline and within 7 days after surgery

Secondary outcomes

  1. Disease stage of prticipants in the NAFLD/NASH group

    Time frame: pre-operative

  2. IL-2, IL-6 and IL-11 expression levels for inter-group comparison of inflammatory status

    Time frame: pre-operative

  3. Correlations of disease stage with inflammatory mediator levels and extrahepatic organ function

    Time frame: 7 days after surgery

07

Study locations

1 site
  • Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine,Tsinghua University
    Beijing, Beijing Municipality 102218, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Nov 2025, 8 months.

Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's 8 months is below that.

Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Mar 11, 2025
Primary completionActual
Nov 13, 2025
CompletionActual
Nov 21, 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945600
Responsible party
Zhifeng Gao (Beijing Tsinghua Chang Gung Hospital, Beijing Tsinghua Chang Gung Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Mar 11, 2025
Primary completion
Nov 13, 2025
Completion
Nov 21, 2025
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion